title: Probing the effect of point mutations at protein-protein interfaces with free energy calculations.
abstract: We have studied the effect of point mutations of the primary binding residue (P1) at the protein-protein interface in complexes of chymotrypsin and elastase with the third domain of the turkey ovomucoid inhibitor and in trypsin with the bovine pancreatic trypsin inhibitor, using molecular dynamics simulations combined with the linear interaction energy (LIE) approach. A total of 56 mutants have been constructed and docked into their host proteins. The free energy of binding could be reliably calculated for 52 of these mutants that could unambiguously be fitted into the binding sites. We find that the predicted binding free energies are in very good agreement with experimental data with mean unsigned errors between 0.50 and 1.03 kcal/mol. It is also evident that the standard LIE model used to study small drug-like ligand binding to proteins is not suitable for protein-protein interactions. Three different LIE models were therefore tested for each of the series of protein-protein complexes included, and the best models for each system turn out to be very similar. The difference in parameterization between small drug-like compounds and protein point mutations is attributed to the preorganization of the binding surface. Our results clearly demonstrate the potential of free energy calculations for probing the effect of point mutations at protein-protein interfaces and for exploring the principles of specificity of hot spots at the interface.
authors.affiliation: Department of Cell and Molecular Biology, Uppsala University, Biomedical Centre, Uppsala, Sweden.
authors.forename: Martin
authors.initials: M
authors.lastname: Almlöf
authors.forename: Johan
authors.initials: J
authors.lastname: Aqvist
authors.forename: Arne O
authors.initials: AO
authors.lastname: Smalås
authors.forename: Bjørn O
authors.initials: BO
authors.lastname: Brandsdal
mesh_terms: D000818:Animals; D001665:Binding Sites; D002417:Cattle; D002918:Chymotrypsin / Q000737:chemistry* / Q000235:genetics*; D018360:Crystallography, X-Ray; D019277:Entropy; D006801:Humans; D019272:Leukocyte Elastase / Q000737:chemistry; D008024:Ligands; D008958:Models, Molecular; D008962:Models, Theoretical; D009154:Mutation; D010196:Pancreatic Elastase / Q000737:chemistry*; D017354:Point Mutation; D011485:Protein Binding; D025941:Protein Interaction Mapping; D017434:Protein Structure, Tertiary; D012680:Sensitivity and Specificity; D055672:Static Electricity; D013816:Thermodynamics; D014357:Trypsin / Q000737:chemistry; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000737:chemistry; D014422:Turkeys; D014965:X-Rays
chemical_list: D008024:Ligands; C039345:ovomucoid inhibitors; D014359:Trypsin Inhibitor, Kazal Pancreatic; D002918:Chymotrypsin; C117608:alpha-chymotrypsin; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase; D014357:Trypsin